By Sriparna Roy and Juveria Tabassum
(Reuters) - Global food and beverage companies from PepsiCo (PEP.O) to Coca-Cola (KO.N) are
focusing on shorter ingredient lists and smaller pack sizes in 2026 as
more people take appetite-suppressing GLP-1 drugs for weight loss.
Companies
that previously took a wait-and-see attitude now see GLP-1s as here to
stay. So far this year, nearly three dozen companies outside the
healthcare industry have mentioned GLP-1 drugs or weight loss on their
earnings conference calls, up from 14 for the same period a year ago,
and just five two years earlier, according to LSEG data.
Diet
changes linked to GLP-1 drug use could mean up to $12 billion in snack
sales lost over the next decade, according to EY-Parthenon estimates.
Adoption of GLP-1 drugs, which suppress appetite and are mainly
prescribed for diabetes and weight loss, more than doubled in the 12
months to December, with about 20% of U.S. households now including at
least one user, according to a PwC analysis.
Peter
ter Kulve, CEO of Magnum Ice Cream, said GLP-1 users continue to eat
treats, but they exhibit "a stark reduction of mindless munching and
binge eating."
Coca‑Cola's incoming top boss urged faster innovation on his first analyst call as CEO-elect last week, while Kraft Heinz’s (KBH.N) new chief halted a planned split of the company and instead announced
$600 million in investments this year to revive long-neglected staples
such as its meat and cold cuts business Oscar Mayer.
Bar chart showing capital spending expected to grow in 2026 for packaged food companies
GLP-1s REWRITE DEMAND
Capital expenditure is expected to rise for most big food companies this year, jumping as much as 23% for General Mills (GIS.N), according to LSEG data.
PepsiCo
has launched a line called "Simply NKD" to reformulate its snacks, such
as Lay's and Gatorade, by removing artificial colors and flavors while
also embracing smaller portion sizes.
"I
think there are more opportunities than threats, but there are both,"
said PepsiCo's CEO Ramon Laguarta on a post-earnings call last week.
Coca-Cola
ramped up production to meet growing demand for its protein-infused
Fairlife milk late last year. General Mills launched higher protein
Cheerios cereal in December 2024 as it grapples with competition for
breakfast foods.
"We
expect GLP-1 and other anti-obesity drugs to have a lasting influence
in the food and nutrition landscape, nudging some consumers towards
smaller portions and more nutrient-dense protein and fiber-forward
foods," the company's CEO Jeffrey Harmening said at the Consumer Analyst
Group of New York (CAGNY) conference on Tuesday.
ALL IN ON R&D
Conagra
Brands is investing in snacks such as its Slim Jim meat sticks, nuts
and seeds, and issued a report last year that highlighted rising demand
for protein‑forward, portion‑controlled and nutrient‑dense foods,
especially among Gen Z and millennials.
"There's
not anyone out there that's not designing, putting R&D dollars
against this trend," said Peter Mangan, managing director at Portage
Point Partners.
Smaller
businesses are seeing the opportunity as well. Snap Kitchen, a private
Austin-based company that provides curated daily meals to roughly 35,000
customers annually, invested in expanding its menu with products
containing higher fiber, lean protein density, and ingredients shown to
promote satiety to reflect changing tastes, said CEO Mitchell Raisch.
"The GLP-1 opportunity has sharpened our focus and accelerated our
pipeline," Raisch said.
GLP-1
users on average consume 40% fewer calories, according to PwC's
analysis of data from consumer insights firm Numerator. Dessert
consumption is down 84%, and alcohol use is down by 33%, while fresh
produce intake is up by more than 70%. Family grocery baskets are 4% to
6% smaller, according to the data, while single-person households have
experienced declines of up to 9%.
"We're
just starting to scratch the surface on the ripple effects of this type
of physiological disruption," said Ali Furman, PwC U.S. consumer
markets leader.
Packaged food stocks lag the S&P 500 in the past year
Reporting by Juveria Tabassum and Sriparna Roy in Bengaluru, Alexander
Marrow in London; editing by David Gaffen and Devika Syamnath
This week on Reuters